News
BITRF
0.042
+3092.31%
0.040
Weekly Report: what happened at BITRF last week (0914-0918)?
Weekly Report · 6d ago
Weekly Report: what happened at BITRF last week (0907-0911)?
Weekly Report · 09/14 09:20
Biotron CEO Dr Michelle Miller Resigns After 24 Years of Service
TipRanks · 09/14 00:47
Weekly Report: what happened at BITRF last week (0831-0904)?
Weekly Report · 09/07 09:18
Biotron Switches Share Registry Provider to Automic
TipRanks · 09/04 01:18
Biotron Updates Investors at Melbourne Biotech Showcase
TipRanks · 09/03 00:32
Weekly Report: what happened at BITRF last week (0824-0828)?
Weekly Report · 08/31 09:20
Biotron Files Updated ASX Corporate Governance Appendix 4G for FY 2026
TipRanks · 08/27 03:48
Biotron Outlines Governance and Diversity Framework for FY2026
TipRanks · 08/27 03:47
Biotron Posts Wider Annual Loss but Boosts Asset Backing Amid Material Uncertainty
TipRanks · 08/27 03:37
Weekly Report: what happened at BITRF last week (0817-0821)?
Weekly Report · 08/24 09:20
Weekly Report: what happened at BITRF last week (0810-0814)?
Weekly Report · 08/17 09:20
Biotron Advances Hepatitis B Candidate BIT-HBV001 Toward Human Trials After Strong Preclinical Data
TipRanks · 08/17 03:57
Weekly Report: what happened at BITRF last week (0803-0807)?
Weekly Report · 08/10 09:19
Weekly Report: what happened at BITRF last week (0727-0731)?
Weekly Report · 08/03 09:19
Weekly Report: what happened at BITRF last week (0720-0724)?
Weekly Report · 07/27 09:20
Weekly Report: what happened at BITRF last week (0713-0717)?
Weekly Report · 07/20 09:19
Biotron Updates Market on Directors’ Shareholding Changes
TipRanks · 07/15 06:57
Weekly Report: what happened at BITRF last week (0706-0710)?
Weekly Report · 07/13 09:19
Biotron Clears First SedRx Milestone After EMA Feedback on Regulatory Pathway
TipRanks · 07/13 01:32
More
Webull provides a variety of real-time BITRF stock news. You can receive the latest news about Biotron through multiple platforms. This information may help you make smarter investment decisions.
About BITRF
Biotron Limited is a clinical-stage biotechnology company. The Company is engaged in developing and commercializing a novel small molecule approach that has the potential to treat several serious viral diseases. Its proprietary primary bacterial cell-based screening platform enables rapid screening for target viroporin proteins, including hepatitis C, HIV-1, Dengue, Zika, Influenza, and Respiratory Syncytial Virus (RSV). The Company has developed a library of over 350 compounds with potential activity against a range of viral diseases. Its lead compound, BIT225, is in Phase II development for the treatment of HIV-1. BIT225 appears to inhibit HIV-1 replication in macrophage reservoir cells offering the potential, when used in combination with other anti-retroviral compounds, to eradicate HIV-1. The Company also owns SedRx, which is a general anesthetic containing alfaxalone.